

## FORM 9

### **NOTICE OF ISSUANCE OR PROPOSED ISSUANCE OF LISTED SECURITIES**

**(or securities convertible or exchangeable into listed securities<sup>1</sup>)**

Name of Listed Issuer:

Symbol(s):

Aura Health Inc. (the "Issuer").	BUZZ
----------------------------------	------

Date: April 16, 2019 Is this an updating or amending Notice:  Yes  No

If yes provide date(s) of prior Notices: February 4 and 27, 2019.

Issued and Outstanding Securities of Issuer Prior to Issuance: 53,297,644 common shares.

#### **Pricing**

Date of news release announcing proposed issuance: February 4, and 27, 2019 or

Date of confidential request for price protection: \_\_\_\_\_

Closing Market Price on Day Preceding the news release: \$0.26 or

Day preceding request for price protection: \_\_\_\_\_

#### **Closing**

Number of securities to be issued: 13,562,387 common shares and 12,623,045 subscription receipts (not including compensation options referred to in Part 1 Section 8(c) and Part 2 Section 8(c) below)

Issued and outstanding securities following issuance: assuming conversion of the Subscription Receipts, 79,483,076 common shares (not including the compensation options referred to in Part 1 Section 8(c) and Part 2 Section 8(c) below)

#### **Instructions:**

1. For private placements (including debt settlement), complete tables 1A and 1B in Part 1 of this form.
2. Complete Table 1A – Summary for all purchasers, excluding those identified in Item 8.
3. Complete Table 1B – Related Persons only for Related Persons
4. If shares are being issued in connection with an acquisition (either as consideration or to raise funds for a cash acquisition) please proceed to Part 2 of this form.
5. An issuance of non-convertible debt does not have to be reported unless it is a significant transaction as defined in Policy 7, in which case it is to be reported on Form 10 – Notice of Proposed Transaction

---

**FORM 9 – NOTICE OF ISSUANCE OR PROPOSED ISSUANCE OF LISTED SECURITIES**

September 2018  
Page 1

6. Post the completed Form 9 to the CSE website in accordance with *Policy 6 – Distributions*. In addition, the completed form must be delivered to [listings@thecse.com](mailto:listings@thecse.com) with an appendix that includes the information in Table 1B for ALL places.

**Part 1. Private Placement**

**Table 1A – Summary**

Each jurisdiction in which purchasers reside	Number of Purchasers	Price per Security	Total dollar value (CDN\$) raised in the jurisdiction
Alberta	5	\$0.22	\$205,040.00
British Columbia	25	\$0.22	\$494,230.00
Ontario	21	\$0.22	\$1,275,239.90
Cayman Islands	1	\$0.22	\$149,820.00
Israel	1	\$0.22	\$27,500.00
Germany	1	\$0.22	\$74,800.00
Switzerland	1	\$0.22	\$50,600.00
Australia	1	\$0.22	\$499,840.00
Total number of purchasers:	57		
Total dollar value of distribution in all jurisdictions:			\$2,777,069.90

**Table 1B – Related Persons**

Full Name & Municipality of Residence of Placee	Number of Securities Purchased or to be Purchased	Purchase price per Security (CDN\$)	Conversion Price (if Applicable) (CDN\$)	Prospectus Exemption	Total Securities Previously Owned, Controlled or Directed	Payment Date(1)	Describe relationship to Issuer (2)
Clickguru Inc. Toronto	150,000	\$0.22		Accredited Investor	510,000 common shares 150,000 warrants		Insider of the Issuer

**FORM 9 – NOTICE OF ISSUANCE OR PROPOSED ISSUANCE OF LISTED SECURITIES**

<sup>1</sup>An issuance of non-convertible debt does not have to be reported unless it is a significant transaction as defined in Policy 7, in which case it is to be reported on Form 10.

1. Total amount of funds to be raised: \$2,777,069.90 .
2. Provide full details of the use of the proceeds. The disclosure should be sufficiently complete to enable a reader to appreciate the significance of the transaction without reference to any other material. To fund the acquisition by Aura of an 80% equity interest in Pharmadrug Production GmbH, a German pharmaceutical distribution company .
3. Provide particulars of any proceeds which are to be paid to Related Persons of the Issuer: Not applicable .  
\_\_\_\_\_ .
4. If securities are issued in forgiveness of indebtedness, provide details of the debt agreement(s) or and the agreement to exchange the debt for securities. Not applicable.
5. Description of securities to be issued:
  - (a) Class Subscription Receipts, each convertible into Units, each Unit consisting of one Common Share and one-half Warrant .
  - (b) Number 12,623,045 (not including the compensation options referred to in Section 8(c) below) .
  - (c) Price per security \$0.22 .
  - (d) Voting rights Yes – Common Shares .
6. Provide the following information if warrants, (options) or other convertible securities are to be issued:
  - (a) Number 6,311,522 warrants (not including the compensation options referred to in Section 8(c) below) .
  - (b) Number of securities eligible to be purchased on exercise of warrants (or options) 6,311,522 common shares (not including the compensation options referred to in Section 8(c) below) .  
\_\_\_\_\_ .
  - (c) Exercise price \$0.28 .
  - (d) Expiry date 24 months from the date of satisfaction of the Escrow Release Conditions for the Subscription Receipts .

7. Provide the following information if debt securities are to be issued:
- (a) Aggregate principal amount N/A .
  - (b) Maturity date N/A .
  - (c) Interest rate N/A .
  - (d) Conversion terms N/A .
  - (e) Default provisions N/A .
8. Provide the following information for any agent's fee, commission, bonus or finder's fee, or other compensation paid or to be paid in connection with the placement (including warrants, options, etc.):
- (a) Details of any dealer, agent, broker or other person receiving compensation in connection with the placement (name, and if a corporation, identify persons owning or exercising voting control over 20% or more of the voting shares if known to the Issuer): Mackie Research Capital Corporation, Haywood Securities Inc., PI Financial Corp., and Foundation Markets Inc. .
  - (b) Cash 7% agent commission .
  - (c) Securities Compensation options to acquire up to 7% of the number of Subscription Receipts sold in the offering .
  - (d) Other 7% agent commission referred to in Section 8(b) above may at the option of the agents be paid in the form of Common Shares based on the issue price .
  - (e) Expiry date of any options, warrants etc. Compensation options expire 24 months following closing .
  - (f) Exercise price of any options, warrants etc. Warrants to be exercisable at a price of \$0.28 .
9. State whether the sales agent, broker, dealer or other person receiving compensation in connection with the placement is Related Person or has any other relationship with the Issuer and provide details of the relationship \_\_\_\_\_
- None .
10. Describe any unusual particulars of the transaction (i.e. tax "flow through" shares, etc.).

Not applicable

---

11. State whether the private placement will result in a change of control.

No

---

12. Where there is a change in the control of the Issuer resulting from the issuance of the private placement shares, indicate the names of the new controlling shareholders. Not applicable
- 
- 

13. Each purchaser has been advised of the applicable securities legislation restricted or seasoning period. All certificates for securities issued which are subject to a hold period bear the appropriate legend restricting their transfer until the expiry of the applicable hold period required by National Instrument 45-102 Resale of Securities.

## Part 2. Acquisition

1. Provide details of the assets to be acquired by the Issuer (including the location of the assets, if applicable). The disclosure should be sufficiently complete to enable a reader to appreciate the significance of the transaction without reference to any other material: The Issuer will acquire \$3 million worth of common shares (the "FSD Shares") in the capital of FSD Pharma Inc. ("FSD"). The number of FSD Shares to be issued to the Issuer will be determined by dividing \$3 million by the 10 day volume weighted average trading price ("VWAP") of the FSD Shares immediately prior to closing. In exchange, the Issuer will issue 13,562,387 common shares in the capital of the Issuer ("Aura Shares").
2. Provide details of the acquisition including the date, parties to and type of agreement (eg: sale, option, license etc.) and relationship to the Issuer. The disclosure should be sufficiently complete to enable a reader to appreciate the significance of the acquisition without reference to any other material: The Issuer will enter into a share exchange agreement with FSD to be dated on or about April 17, 2019 (the "Share Exchange Agreement")
3. Provide the following information in relation to the total consideration for the acquisition (including details of all cash, securities or other consideration) and any required work commitments:
- (a) Total aggregate consideration in Canadian dollars: \_\_\_\_\_
- (b) Cash: \_\_\_\_\_

- (c) Securities (including options, warrants etc.) and dollar value: 13,562,387 common shares at deemed value of \$0.22 per share .
- (d) Other: \_\_\_\_\_ .
- (e) Expiry date of options, warrants, etc. if any: \_\_\_\_\_ .
- (f) Exercise price of options, warrants, etc. if any: \_\_\_\_\_ .
- (g) Work commitments: \_\_\_\_\_ .
4. State how the purchase or sale price was determined (e.g. arm's-length negotiation, independent committee of the Board, third party valuation etc). Arm's-length negotiation.
5. Provide details of any appraisal or valuation of the subject of the acquisition known to management of the Issuer: \_\_\_\_\_  
N/A .
6. The names of parties receiving securities of the Issuer pursuant to the acquisition and the number of securities to be issued are described as follows:

Name of Party (If not an individual, name all insiders of the Party)	Number and Type of Securities to be Issued	Dollar value per Security (CDN\$)	Conversion price (if applicable)	Prospectus Exemption	Total Securities, Previously Owned, Controlled or Directed by Party	Describe relationship to Issuer <sup>(1)</sup>
FSD Pharma Inc.	<u>13,562,387 common shares</u>	\$0.22		Asset Acquisition		Arm's length

(1) Indicate if Related Person

7. Details of the steps taken by the Issuer to ensure that the vendor has good title to the assets being acquired: \_\_\_\_\_  
N/A .
8. Provide the following information for any agent's fee, commission, bonus or finder's fee, or other compensation paid or to be paid in connection with the acquisition (including warrants, options, etc.):

- (a) Details of any dealer, agent, broker or other person receiving compensation in connection with the acquisition (name, and if a corporation, identify persons owning or exercising voting control over 20% or more of the voting shares if known to the Issuer): Mackie Research Capital Corporation.
- (b) Cash 6% of the value of the FSD Shares .
- (c) Securities Compensation Options to acquire 6% of the number of Aura Shares issued to FSD .
- (d) Other \_\_\_\_\_ .
- (e) Expiry date of any options, warrants etc. 24 months from February 27, 2019 \_\_\_\_\_ .
- (f) Exercise price of any options, warrants etc. Compensation Options exercisable at \$0.22 per unit of the Company (each, a "Unit"). Each Unit comprised of one Aura Share and one-half of one common share purchase warrant of the Issuer (each whole common share purchase warrant, a "Warrant"). With each Warrant exercisable at a price of \$0.28 for 24 months from the date of satisfaction of certain escrow release conditions. \_\_\_\_\_ .

9. State whether the sales agent, broker or other person receiving compensation in connection with the acquisition is a Related Person or has any other relationship with the Issuer and provide details of the relationship. The agent is not a Related Person and does not have any other relationship with the Issuer.

10. If applicable, indicate whether the acquisition is the acquisition of an interest in property contiguous to or otherwise related to any other asset acquired in the last 12 months. \_\_\_\_\_  
 \_\_\_\_\_ N/A \_\_\_\_\_  
 \_\_\_\_\_

## Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance on behalf of the Issuer.
2. As of the date hereof there is not material information concerning the Issuer which has not been publicly disclosed.
3. the Issuer has obtained the express written consent of each applicable individual to:
  - (a) the disclosure of their information to the Exchange pursuant to this Form or otherwise pursuant to this filing; and
  - (b) the collection, use and disclosure of their information by the Exchange in the manner and for the purposes described in Appendix A or as otherwise identified by the Exchange, from time to time
4. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CSE Policy 1).
5. All of the information in this Form 9 Notice of Issuance of Securities is true.

Dated April 16, 2019.

Daniel Cohen  
Name of Director or Senior  
Officer

'Daniel Cohen'  
Signature

CEO  
Official Capacity



## Appendix A

### PERSONAL INFORMATION COLLECTION POLICY REGARDING FORM 9

The Canadian Securities Exchange and its subsidiaries, affiliates, regulators and agents (collectively, “CSE or the “Exchange”) collect and use the information (which may include personal or other information) which has been provided in Form 9 for the following purposes:

- To determine whether an individual is suitable to be associated with a Listed Issuer;
- To determine whether an issuer is suitable for listing;
- To determine whether allowing an issuer to be listed or allowing an individual to be associated with a Listed Issuer could give rise to investor protection concerns or could bring the Exchange into disrepute;
- To conduct enforcement proceedings;
- To ensure compliance with Exchange Requirements and applicable securities legislation; and
- To fulfil the Exchange’s obligation to regulate its marketplace.

The CSE also collects information, including personal information, from other sources, including but not limited to securities regulatory authorities, law enforcement and self-regulatory authorities, regulation service providers and their subsidiaries, affiliates, regulators and agents. The Exchange may disclose personal information to these entities or otherwise as provided by law and they may use it for their own investigations.

The Exchange may use third parties to process information or provide other administrative services. Any third party will be obliged to adhere to the security and confidentiality provisions set out in this policy.

All personal information provided to or collected by or on behalf of The Exchange and that is retained by The Exchange is kept in a secure environment. Only those employees who need to know the information for the purposes listed above are permitted access to the information or any summary thereof. Employees are instructed to keep the information confidential at all times.

Information about you that is retained by the Exchange and that you have identified as inaccurate or obsolete will be corrected or removed.

If you wish to consult your file or have any questions about this policy or our practices, please write the Chief Privacy Officer, Canadian Securities Exchange, 220 Bay Street – 9th Floor, Toronto, ON, M5J 2W4.